Singleron Biotechnologies Secures $30 Million Series A Funding to Advance Single-Cell Multi-Omics Platform

Singleron Biotechnologies (“Singleron”), a company focused on high-throughput single-cell multi-omics platform products, recently secured $30 million in Series A financing. The round was led by Lilly Asia Ventures, with participation from CDH Investments, ARCH Venture Partners, Tencent, and the Guoxin Guoxin Dongwu Overseas Fund (managed by Chenling Capital). Existing investors Sherpa Capital and Huachuang Capital also continued their support.

This financing round will enable Singleron to accelerate the further development and clinical translation of its single-cell sequencing platform products; promote the application of single-cell sequencing technologies and data in drug development; expedite the domestic commercialization of its independently developed products; and launch international operations. This marks Singleron’s third round of financing, following its seed round led by Yuanhe Yuandian in 2018 and its Pre-A round led by Sherpa Capital in 2019. To date, Singleron’s total fundraising has exceeded RMB 300 million.

Founded in 2018, Singleron is dedicated to the independent development and clinical translation of high-throughput single-cell multi-omics platform products. Since its establishment, the company has experienced rapid growth and now boasts an internationally leading one-stop high-throughput single-cell sequencing platform. It provides comprehensive solutions ranging from tissue sample processing, high-throughput single-cell isolation, and sequencing library construction to data analysis and exploration of clinical significance. Its current product portfolio includes the independently developed and manufactured Singleron Matrix™ automated system for single-cell sequencing library preparation, the GEXSCOPE® high-throughput single-cell sequencing kit, the CeleScope™ bioinformatics analysis software, and the SynEcoSys™ single-cell database. Singleron has served over 160 renowned hospitals, pharmaceutical companies, and research institutions.

As a groundbreaking new technology, single-cell sequencing is poised to gradually replace traditional bulk-sample next-generation sequencing. Currently, the global potential research market for single-cell sequencing has reached $13 billion. The application prospects of single-cell analysis in clinical practice and drug development are even more extensive; it can replace or complement existing technologies in molecular, cytological, and histopathological testing, and can also be utilized in the development of systemic therapies such as emerging immunotherapies, cell therapies, and gene therapies. Adhering to the innovative philosophy of “investigating things to acquire knowledge, and understanding the subtle to comprehend the fundamental,” Singleron is dedicated to advancing simple and reliable high-throughput single-cell omics technologies, establishing them as next-generation tools for cellular and molecular pathology and blood testing. This enables single-cell omics to serve precision medicine, drug development, and health management with high accuracy, high sensitivity, and high resolution.

Lilly Asia Ventures (LAV), established in 2008, is a leading venture capital fund focused on investments in the life sciences and healthcare sectors, with offices in Shanghai, China; Hong Kong, China; and Silicon Valley, USA. LAV is committed to being a trusted partner for outstanding entrepreneurs seeking smart capital, co-creating great companies that develop breakthrough products to combat diseases and improve human health.

CDH Investments, established in 2002, is one of China’s largest alternative asset management firms, with assets under management totaling RMB 150 billion. The firm has invested in more than 200 companies, over 70 of which are listed on domestic and international stock exchanges. By cultivating a portfolio of industry-leading brands, CDH Investments has become a significant force driving the vitality of China’s economy. Its core philosophy is to partner with entrepreneurs and create long-term value.

ARCH Venture Partners is a premier global early-stage venture capital firm in the healthcare and life sciences sector, founded in the United States in 1986. For over three decades, it has been dedicated to making early investments in innovative companies with breakthrough technologies. It was an early investor in many well-known life sciences companies, including Illumina, Twist Bioscience, Quanterix, Alnylam Pharmaceuticals, Juno Therapeutics, and bluebird bio.

Guoxin Guoxin Dongwu Overseas Fund (Chenling Capital Management) is a US dollar-denominated fund specializing in investments in healthcare, high-end equipment manufacturing, and TMT sectors. Key portfolio companies under Chenling Capital’s healthcare division include Innovent Biologics, Akeso Biopharma, Tigermed, RemeGen, MicroPort CardioFlow, Antengene Corporation, and Grail.